Free Trial

This company has been marked as potentially delisted and may not be actively trading.

OvaScience (OVAS) Competitors

OvaScience logo

OVAS vs. WHWK, CNTN, MENS, ANTX, and TTRX

Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Whitehawk Therapeutics (WHWK), Hillstream Biopharma (CNTN), Jyong Biotech (MENS), Anthem (ANTX), and Turn Therapeutics (TTRX).

How does OvaScience compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and OvaScience (NASDAQ:OVAS) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of OvaScience shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 7.4% of OvaScience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Whitehawk Therapeutics has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. OvaScience's return on equity of -47.06% beat Whitehawk Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Whitehawk TherapeuticsN/A -62.88% -58.98%
OvaScience -10,128.37%-47.06%-42.39%

Whitehawk Therapeutics has higher revenue and earnings than OvaScience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Whitehawk Therapeutics$7.14M29.15-$20.60M$0.478.96
OvaScience$290K192.74-$50.97MN/AN/A

Whitehawk Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 66.27%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Whitehawk Therapeutics is more favorable than OvaScience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
OvaScience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Whitehawk Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than OvaScience. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 0 mentions for OvaScience. Whitehawk Therapeutics' average media sentiment score of 1.16 beat OvaScience's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Whitehawk Therapeutics Positive
OvaScience Neutral

Summary

Whitehawk Therapeutics beats OvaScience on 10 of the 14 factors compared between the two stocks.

How does OvaScience compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and OvaScience (NASDAQ:OVAS) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

In the previous week, Hillstream Biopharma's average media sentiment score of 0.00 equaled OvaScience'saverage media sentiment score.

Company Overall Sentiment
Hillstream Biopharma Neutral
OvaScience Neutral

Hillstream Biopharma has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, indicating that its share price is 211% more volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
OvaScience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Hillstream Biopharma has higher earnings, but lower revenue than OvaScience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hillstream BiopharmaN/AN/A-$35.92M-$3.99N/A
OvaScience$290K192.74-$50.97MN/AN/A

Hillstream Biopharma has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. Hillstream Biopharma's return on equity of -35.59% beat OvaScience's return on equity.

Company Net Margins Return on Equity Return on Assets
Hillstream BiopharmaN/A -35.59% -27.05%
OvaScience -10,128.37%-47.06%-42.39%

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 22.5% of OvaScience shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Comparatively, 7.4% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Hillstream Biopharma beats OvaScience on 5 of the 9 factors compared between the two stocks.

How does OvaScience compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and OvaScience (NASDAQ:OVAS) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

In the previous week, Jyong Biotech had 2 more articles in the media than OvaScience. MarketBeat recorded 2 mentions for Jyong Biotech and 0 mentions for OvaScience. Jyong Biotech's average media sentiment score of 0.00 equaled OvaScience'saverage media sentiment score.

Company Overall Sentiment
Jyong Biotech Neutral
OvaScience Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
OvaScience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Jyong Biotech has higher earnings, but lower revenue than OvaScience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/AN/AN/AN/A
OvaScience$290K192.74-$50.97MN/AN/A

Jyong Biotech has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. Jyong Biotech's return on equity of 0.00% beat OvaScience's return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
OvaScience -10,128.37%-47.06%-42.39%

22.5% of OvaScience shares are held by institutional investors. 7.4% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Jyong Biotech beats OvaScience on 5 of the 8 factors compared between the two stocks.

How does OvaScience compare to Anthem?

Anthem (NASDAQ:ANTX) and OvaScience (NASDAQ:OVAS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

90.5% of Anthem shares are held by institutional investors. Comparatively, 22.5% of OvaScience shares are held by institutional investors. 20.8% of Anthem shares are held by company insiders. Comparatively, 7.4% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anthem has higher earnings, but lower revenue than OvaScience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnthemN/AN/A-$35.17M-$1.16N/A
OvaScience$290K192.74-$50.97MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anthem
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
OvaScience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Anthem has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. OvaScience's return on equity of -47.06% beat Anthem's return on equity.

Company Net Margins Return on Equity Return on Assets
AnthemN/A -55.04% -49.13%
OvaScience -10,128.37%-47.06%-42.39%

Anthem has a beta of -0.95, indicating that its share price is 195% less volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, indicating that its share price is 211% more volatile than the S&P 500.

In the previous week, Anthem had 6 more articles in the media than OvaScience. MarketBeat recorded 6 mentions for Anthem and 0 mentions for OvaScience. Anthem's average media sentiment score of 0.00 equaled OvaScience'saverage media sentiment score.

Company Overall Sentiment
Anthem Neutral
OvaScience Neutral

Summary

Anthem beats OvaScience on 6 of the 10 factors compared between the two stocks.

How does OvaScience compare to Turn Therapeutics?

OvaScience (NASDAQ:OVAS) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

22.5% of OvaScience shares are owned by institutional investors. 7.4% of OvaScience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Turn Therapeutics has lower revenue, but higher earnings than OvaScience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OvaScience$290K192.74-$50.97MN/AN/A
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A

Turn Therapeutics has a consensus price target of $8.00, indicating a potential upside of 116.22%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Turn Therapeutics is more favorable than OvaScience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OvaScience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Turn Therapeutics has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. Turn Therapeutics' return on equity of 0.00% beat OvaScience's return on equity.

Company Net Margins Return on Equity Return on Assets
OvaScience-10,128.37% -47.06% -42.39%
Turn Therapeutics N/A N/A N/A

In the previous week, OvaScience's average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score.

Company Overall Sentiment
OvaScience Neutral
Turn Therapeutics Neutral

Summary

Turn Therapeutics beats OvaScience on 7 of the 10 factors compared between the two stocks.

Get OvaScience News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVAS vs. The Competition

MetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$55.90M$883.41M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E RatioN/A1.7129.2527.07
Price / Sales192.74119.23504.6873.43
Price / CashN/A20.0743.3053.90
Price / Book0.877.609.676.69
Net Income-$50.97M-$4.80M$3.55B$332.64M

OvaScience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OVAS
OvaScience
N/A$1.56
flat
N/AN/A$55.90M$290KN/AN/A
WHWK
Whitehawk Therapeutics
4.0577 of 5 stars
$4.03
-3.4%
$7.00
+73.7%
N/A$196.81M$7.15M8.5721
CNTN
Hillstream Biopharma
0.0782 of 5 stars
$3.41
+1.2%
N/AN/A$190.93MN/AN/A2
MENS
Jyong Biotech
N/A$2.19
-3.5%
N/AN/A$166.50MN/AN/A31
ANTX
Anthem
0.1857 of 5 stars
$4.34
+1.4%
$2.00
-53.9%
N/A$154.06MN/AN/AN/A

Related Companies and Tools


This page (NASDAQ:OVAS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners